The global heparin market size is expected to reach USD 7.4 billion by 2026. It is projected to register a CAGR of 1.6% during the forecast period. Rising prevalence cardiovascular disorders, deep vein thrombosis, and renal diseases among other chronic diseases is expected to boost the growth.
Access Sample Report of this report @ https://www.radiantinsights.com/research/heparin-market/request-sample
According to the data published in the American Heart Association, in 2018, approximately 92.1 million American adults were living with some form of cardiovascular diseases. Coronary heart disease is one of the leading cause of deaths in U.S. Furthermore, it was estimated that more than 23.6 million deaths will be observed by 2030 due to cardiovascular diseases.
Increasing demand for transfusion of blood, blood components, and plasma derivatives during surgical procedures, treatment of infectious diseases, and increasing survival rate are high impact rendering drivers for growth of the heparin market during the forecast period. Increasing demand for RBCs and platelets by various hospital divisions and clinics is expected to have a positive impact on the growth.
Growing geriatric population is anticipated to propel the market growth. According to an article published in 2018 in the United States Census Bureau, it is estimated that by 2035, population aged 65 years and above is expected to reach 78 million whereas children under the age of 18 may reach around 76.7million.
Rising incidence of immunological diseases, thrombosis, and hemostasis is likely to result in high demand for therapeutic plasma proteins. Manufacturing of plasma proteins led to an increase in the demand for purified plasma, further expected to fuel the market over the forecast period.
Further key findings from the report suggest:
- Low molecular weight heparin led the type segment in 2018 owing to its more predictable anticoagulant effect
- In 2018, ultra-low molecular weight heparin was estimated to be the fastest growing segment, owing to commercialization of enhanced version of products with improved pharmacological effects
- Subcutaneous route of administration led the market in 2018 and is estimated to be the fastest growing segment over the forecast period due to ease of administration
- Coronary artery disease was considered to be the largest application segment in 2018 and venous thromboembolism is projected to be the fastest growing segment in near future
- In 2018, outpatient led the end use segment and was estimated to register the fastest growth in the forthcoming years
- North America held the largest market share in 2018 owing to increasing prevalence of cardiovascular disorders and sports injuries. Asia Pacific is estimated to be the fastest growing segment over the forecast period
- Some of the key companies operating in the heparin market are GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy's Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; and Teva Pharmaceutical Industries Ltd
Browse Full Report With TOC @ https://www.radiantinsights.com/research/heparin-market
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: [email protected]
Venous Thromboembolism Treatment Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the venous thromboembolism treatment market include Argon Medical Devices, Arjo, Boston Scientific, Cardinal Health (Medtronic), Cook Medical, DJO Global, Koninklijke Philips N.V., and Stryker.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Venous Thromboembolism Treatment Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/venous-thromboembolism-treatment-market/download-sampleMarket DynamicsThe key drivers behind global venous thromboembolism treatment market growth are increasing incidence of VTE and increasing awareness about the existing treatment options.
Introduction of new VTE treatment devices, increasing the number of treatment choices for patients will contribute significantly towards VTE treatment market.
Furthermore, technological advancements in VTE treatment, such as, development of heparins and associated inhibitors with low molecular weight are expected to bring lucrative growth opportunities for VTE market.
